Alphamab Oncology Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 515

Employees

  • Stock Symbol
  • 09966

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.65
  • (As of Friday Closing)

Alphamab Oncology General Information

Description

Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 218 XingHu Street
  • Suzhou Industrial Park, Bldg. C23
  • Suzhou, Jiangsu 215125
  • China
+86 0512
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • 218 XingHu Street
  • Suzhou Industrial Park, Bldg. C23
  • Suzhou, Jiangsu 215125
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alphamab Oncology Stock Performance

As of 20-Nov-2026, Alphamab Oncology’s stock price is $0.65. Its current market cap is $628M with 964M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.65 $0.68 $0.64 - $1.56 $628M 964M 1.18M -$0.03

Alphamab Oncology Financials Summary

As of 30-Jun-2026, Alphamab Oncology has a trailing 12-month revenue of $74M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 684,514 1,030,095 276,883 640,543
Revenue 74,033 78,739 89,204 30,923
EBITDA (18,844) (10,722) 28,436 (28,741)
Net Income (25,149) (15,844) 23,182 (29,766)
Total Assets 318,554 299,722 307,086 301,486
Total Debt 39,505 17,577 25,474 36,267
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alphamab Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alphamab Oncology‘s full profile, request access.

Request a free trial

Alphamab Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADC
Pharmaceuticals
Suzhou, China
515 As of 2026

Shanghai, China
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alphamab Oncology Competitors (59)

One of Alphamab Oncology’s 59 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abbisko Medicine Formerly VC-backed Shanghai, China
GT Biopharma Corporation San Francisco, CA
BeOne Medicines Formerly PE-Backed Beijing, China
EMD Serono Corporation Boston, MA
Decode Genetics Formerly VC-backed Reykjavik, Iceland
You’re viewing 5 of 59 competitors. Get the full list »

Alphamab Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alphamab Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alphamab Oncology‘s full profile, request access.

Request a free trial

Alphamab Oncology Investments (3)

Alphamab Oncology’s most recent deal was a Secondary Transaction - Private with Panomix. The deal was made on 19-Apr-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Panomix 19-Apr-2019 Secondary Transaction - Private Laboratory Services (Healthcare)
SmartNuclide 21-Mar-2016 Seed Round Drug Discovery
Panomix 01-Jan-2016 Early Stage VC Laboratory Services (Healthcare)
To view Alphamab Oncology’s complete investments history, request access »

Alphamab Oncology ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.01 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Alphamab Oncology’s complete esg history, request access »

Alphamab Oncology FAQs

  • When was Alphamab Oncology founded?

    Alphamab Oncology was founded in 2008.

  • Where is Alphamab Oncology headquartered?

    Alphamab Oncology is headquartered in Suzhou, China.

  • What is the size of Alphamab Oncology?

    Alphamab Oncology has 515 total employees.

  • What industry is Alphamab Oncology in?

    Alphamab Oncology’s primary industry is Pharmaceuticals.

  • Is Alphamab Oncology a private or public company?

    Alphamab Oncology is a Public company.

  • What is Alphamab Oncology’s stock symbol?

    The ticker symbol for Alphamab Oncology is 09966.

  • What is the current stock price of Alphamab Oncology?

    As of 20-Nov-2026 the stock price of Alphamab Oncology is $0.65.

  • What is the current market cap of Alphamab Oncology?

    The current market capitalization of Alphamab Oncology is $628M.

  • What is Alphamab Oncology’s current revenue?

    The trailing twelve month revenue for Alphamab Oncology is $74M.

  • Who are Alphamab Oncology’s competitors?

    Abbisko Medicine, GT Biopharma, BeOne Medicines, EMD Serono, and Decode Genetics are some of the 59 competitors of Alphamab Oncology.

  • What is Alphamab Oncology’s annual earnings per share (EPS)?

    Alphamab Oncology’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process